EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

STING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma

Tyler MacNeil, Thomas J Hayman iD, Shengguo Li iD, Myrto Moutafi iD, Sandra Martinez-Morilla iD, Ioannis A Vathiotis, Rong Hu, Paul M Harari, Barbara Burtness iD, Hao Liu iD, Randall J Kimple iD, David L Rimm iD und 1 weitere

JNCI Cancer Spectrum · 2026

DOI: 10.1093/jncics/pkaf126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2026. Verfasst von Tyler MacNeil und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yale School of Medicine, New Haven, CT, United States. Hauptthemen laut MEDLINE: Membrane Proteins, Biomarkers, Tumor, Head and Neck Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCR NIH HHS, NCI NIH HHS, Rutgers Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The TMEM173/STING protein is linked to therapeutic resistance in preclinical models of HNSCC (Head and neck squamous cell carcinoma). To evaluate STING as a biomarker, quantitative immunofluorescence (QIF) was performed on a tissue microarray (TMA) cohort of primary HNSCC (n = 72). Cytokeratin and 4,6-diamidino-2-phenylindole (DAPI) staining were used to differentiate between tumor or stromal compartments, and patient groups were dichotomized based on STING QIF scores. HNSCCs display variable STING protein levels in both tumor cell and stromal compartments. STING QIF score in tumor cells is associated with p16 positivity, with similar nonsignificant trends observed for stromal QIF values. In cohort 1, elevated STING levels in either tumor cells (P = .029) or stroma (P = .023) significantly improved DFS. These findings were validated in a second oropharyngeal HNSCC TMA cohort (n = 92) where borderline or significant differences in DFS were observed for elevated STING in tumor cells (P = .066) or the stroma (P = .028). A more detailed breakdown of failure patterns in cohort 2 revealed that elevated STING in tumor (P = .015) or stroma (P = .054) predicts local-regional control, and a trend for reduced distant failure was also observed for elevated stromal STING (P = .067). Local-regional recurrence was rare in HPV+ tumors and occurred only with low STING expression. In multivariate analysis, p16 was a significant predictor for local control, whereas elevated STING was of borderline significance (P = .051). These results suggest that STING protein levels in the tumor cell are a biomarker for predicting HNSCC local control after radiation therapy, and elevated STING in tumor stroma may be associated with a reduced risk of distant failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Membrane ProteinsBiomarkers, TumorHead and Neck NeoplasmsCarcinoma, Squamous CellHumansSTING ProteinFemaleMaleMiddle AgedCyclin-Dependent Kinase Inhibitor p16Disease-Free SurvivalSquamous Cell Carcinoma of Head and NeckAgedTissue Array AnalysisOropharyngeal NeoplasmsFluorescent Antibody TechniqueNeoplasm Recurrence, LocalTreatment Failure

Substanzen

Membrane ProteinsBiomarkers, TumorSTING ProteinSTING1 protein, humanCyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human

Autor:innen und Institutionen

  • Department of Pathology, Yale School of Medicine, New Haven, CT, United States.
  • Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT, United States.
  • Biostatistics Shared Resource, Rutgers Cancer Institute, New Brunswick, NJ, United States.
  • Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
  • Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States.
  • Department of Medicine, Yale University School of Medicine, New Haven, CT, United States.

ORCID-Profile: Thomas J Hayman, Shengguo Li, Myrto Moutafi, Sandra Martinez-Morilla, Barbara Burtness, Hao Liu, Randall J Kimple, David L Rimm, Joseph N Contessa

Förderung

  • NIDCR NIH HHS
  • NCI NIH HHS
  • Rutgers Cancer Institute
  • National Cancer Institute (NCI)
  • Specialized Program of Research Excellence (SPORE)
  • UW Carbone Cancer Center

Zitieren

APA

MacNeil, T., Hayman, T. J., Li, S., Moutafi, M., Martinez-Morilla, S., Vathiotis, I. A., Hu, R., Harari, P. M., Burtness, B., Liu, H., Kimple, R. J., Rimm, D. L., & Contessa, J. N. (2026). STING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf126

Vancouver

MacNeil T, Hayman TJ, Li S, Moutafi M, Martinez-Morilla S, Vathiotis IA, et al. STING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkaf126

BibTeX
@article{MacNeil2026,
  author = {MacNeil, Tyler and Hayman, Thomas J and Li, Shengguo and Moutafi, Myrto and Martinez-Morilla, Sandra and Vathiotis, Ioannis A and Hu, Rong and Harari, Paul M and Burtness, Barbara and Liu, Hao and Kimple, Randall J and Rimm, David L and Contessa, Joseph N},
  title = {STING predicts patterns of failure in locally advanced head and neck squamous cell carcinoma},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  doi = {10.1093/jncics/pkaf126}
}
Kostenlos starten →